Notes: -N is the total number of subjects.
-Population for SPIRIT PRIME consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8 hours post index procedure and hospital discharge.
-TLF includes cardiac death, target vessel MI or clinically indicated TLR.
-Time frame includes follow-up window (1-year: 365 Ϯ 28 days, 2-year: 730 Ϯ 28 days).
-TLF from hierarchical counts; other outcomes from non-hierarchical counts.
-WHO: World Health Organization.
-ARC: Academic Research Consortium.
Conclusions:
The SPIRIT PRIME study demonstrated sustained 2-year safety and efficacy of the new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates in both core size and long lesion cohorts and no new ARC definite/probable ST events in either arm.
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Abstract Withdrawn Background: This study was sought to investigate the impact of complete revascularization (CR) vs. incomplete revascularization (IR) on long-term outcomes in patients with multivessel coronary disease (MVD) in current practice of percutaneous coronary intervention (PCI). Methods: Between April 2004 and November 2010, 7376 consecutive patients with MVD underwent PCI at our center. Patients who underwent prior CABG and those who had an acute myocardial infarction (MI) within 24 hours before revascularization or presented with cardiogenic shock were excluded. Results: Among 7065 patients with MVD undergoing PCI treatment, angiographic CR was performed in 1188 patients (16.8%), and proximal CR in 2053 patients (29.1%). The study found that either angiographic or proximal IR were associated with significantly higher estimated 3-year rate of cardiac death (2.55% vs. 1.13%, log-rank pϭ0.016; and 2.70% vs. 1.43%, log-rank pϭ0.024; respectively). After adjustment for differences in baseline characteristics between IR and CR patients, angiographic IR was associated with a significantly higher rate of cardiac death (adjusted hazards ratio [HR] Background: PCI stent inflation pressure correlates to angiographic lumen improvement and stent expansion but the relation to outcome is not clarified. Using comprehensive registry data our aim was to evaluate how stent inflation pressure influences restenosis and stent thrombosis following PCI. Methods: We evaluated all consecutive coronary stent implantations in Sweden from January 1, 2008, to October 26, 2011 using data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). We used logistic regression and Cox proportional hazard modeling to estimate risk of outcomes with different balloon pressures. Results: In total, 93 697 stents were eligible for analysis and divided into five different pressure interval groups: Յ15 atm, 16-17 atm, 18-19 atm, 20-21 atm and Ն22 atm. The risks of stent thrombosis (Fig.) and restenosis were significantly higher in the Յ15 atm, 18-19 atm and Ն22 atm groups (but not in the 16-17 atm group) compared to the 20-21 atm group. Post-dilatation was associated with a higher restenosis risk ratio (RR) of 1.22 (95% confidence interval (CI) 1.14-1.32, PϽ0.001) but stent thrombosis did not differ statistically between procedures with or without post-dilatation. Conclusions: Our retrospective study identified a possible optimal stent inflation pressure of 20-21 atm during PCI which was associated with a lower risk of stent thrombosis and restenosis. Post-dilatation might increase restenosis risk. criteria included acute or recent myocardial infarction (MI), left ventricular ejection fraction Ͻ30%, left main or ostial location, major bifurcation disease, chronic total occlusion, and target vessel thrombus. Routine angiographic follow-up was not performed. Planned clinical follow-up is at 1, 6, 12, and 18 months, and annually to 5 years. Results: Patients were predominantly male (62.7%), and 30.0% presented with medically treated diabetes. At baseline, target lesion length was 24.38Ϯ8.21mm and reference vessel diameter was 2.56Ϯ0.40mm. The study met its primary endpoint of 12-month target lesion failure (composite of target vessel related cardiac death/MI and ischemia-driven target lesion revascularization) with a rate of 3.2%, which was not significantly different (pϽ0.001) than a prespecified performance goal of 19.4% (based on historical outcomes with 32mm paclitaxel-eluting stents, the only long drug-eluting stent approved in the US when PLATINUM LL was initiated). At 1-year follow-up, there were 3 instances of target lesion revascularization (3.1%), 1 non-cardiac death, and no cardiac deaths, MIs, or stent thromboses. Two-year clinical follow-up will be reported.
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Two-Year Outcomes Following Implantation of 32mm and 38mm Platinum Chromium Everolimus Eluting Element Stents in Long Coronary Lesions
Conclusions:
The 1-year results of the PLATINUM LL study support the use of the PROMUS Element 32mm and 38mm stents in the treatment of long coronary lesions. Two-year results will be available for presentation for the first time at TCT in October 2012. 
TCT-613
